Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5462 DDI Study with Midazolam, Rosuvastatin, and Digoxin
NCT05395117Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD5462 in heart failure (HF) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under the concentration-versus-time curve from pre-dose extrapolated to infinite time, Area under the concentration-versus-time curve from pre-dose to last quantifiable concentration and 1 more. Started Jun 2022; status: completed.
02
Drugs
AZD5462
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05395117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395117.